BETHESDA, Md.--(BUSINESS WIRE)--TNI BioTech, Inc. (OTCQB:TNIB) and Laboratorios Ramos announced today that they entered a manufacturing and supply agreement for the production of Low Dose Naltrexone (“LDN”) for commercial use. This agreement enables TNIB to focus on the development and commercialization of therapeutic treatments for...
More...
